Ambit Biosciences Announces Presentations Of Data From Clinical...

"We look forward to further discussing the abstracts once publically released in May." Abstract No.: 7100 Title: Final Results of a Randomized Phase 2 Study Showing the Clinical Benefit of Quizartinib in Patients with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia Presenter: Abstract No.: 7093 Title: The Benefit of Treatment with ... (more)

http://ift.tt/1hjxOBS